Recombinant Cynomolgus Monkey PD-L1/B7-H1 Fc Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9326-B7

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
9326-B7-100
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

XP_005581836

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all PD-L1/B7-H1 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived cynomolgus monkey PD-L1/B7-H1 protein
Cynomolgus Monkey PD-L1
(Phe19-Thr239)
Accession # XP_005581836		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Phe19

Predicted Molecular Mass

52 kDa

SDS-PAGE

58-75 kDa, reducing conditions

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes.
The ED50 for this effect is 2-10 μg/mL.

Reviewed Applications

Read 1 review rated 5 using 9326-B7 in the following applications:

Scientific Data Images for Recombinant Cynomolgus Monkey PD-L1/B7-H1 Fc Protein, CF

Recombinant Cynomolgus Monkey PD-L1/B7-H1 Fc Protein Bioactivity

Recombinant Cynomolgus Monkey PD-L1/B7-H1 Fc Protein Bioactivity

Recombinant Cynomolgus Monkey PD-L1/B7-H1 Fc Chimera (Catalog # 9326-B7) inhibits anti-CD3 antibody-induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 2-10 μg/mL.

Formulation, Preparation and Storage

9326-B7
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 200 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PD-L1/B7-H1

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1, 2). Mature cynomolgus B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 30 aa cytoplasmic domain. Within the ECD, cynomolgus B7-H1 shares 92%, 72%, and 72% aa sequence identity with human, mouse, and rat B7-H1, respectively. In addition, cynomolgus B7-H1 shares 98%, 94%, 94%, 88%, 78%, 98%, 95%, 94%, and 94% aa sequence identity with rhesus macaque, chimpanzee, sumatran orangutan, white-tufted-ear marmoset, Garnett's greater bushbaby, olive baboon, green monkey, western lowland gorilla, and northern white-cheeked gibbon B7-H1, respectively. B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (3-6), keratinocytes (7, 8), endothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (10, 11). B7-H1 is a B7 ligand and binds to B7-1/CD80 and PD-1 receptors on T cells (6, 7, 11-14). It suppresses T cell activation and proliferation (4, 7, 13, 15) and induces the apoptosis of activated T cells (10). It plays a role in the development of immune tolerance by promoting T cell anergy (6, 13) and enhancing regulatory T cell development (15). B7-H1 favors the development of
anti-inflammatory IL-10 and IL-22 producing dendritic cells (4, 9) and inhibits the development of Th17 cells (15). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (5, 8, 11, 14). B7-H1/PD-1 coinhibitory pathway was exploited therapeutically resulting in remarkable outcomes with 20-90% response in various types of cancer (16).

References

  1. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
  2. Dong, H. et al. (1999) Nat. Med. 5:1365.
  3. Tamura, H. et al. (2001) Blood 97:1809.
  4. Chen, L. et al. (2007) J. Immunol. 178:6634.
  5. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
  6. Tsushima, F. et al. (2007) Blood 110:180.
  7. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
  8. Cao, Y. et al. (2010) Cancer Res. 71:1235.
  9. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
  10. Dong, H. et al. (2002) Nat. Med. 8:793.
  11. Azuma, T. et al. (2008) Blood 111:3635.
  12. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
  13. Park, J.-J. et al. (2010) Blood 116:1291.
  14. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
  15. Herold, M. et al. (2015) J. Immunol. 195:3584.
  16. Bardhan K. et al. (2016); Front Immunol. 7:550.

Long Name

Programmed Death Ligand 1

Alternate Names

B7-H1, B7H1, CD274, PDCD1L1, PDCD1LG1, PDL1

Entrez Gene IDs

29126 (Human); 60533 (Mouse); 499342 (Rat); 574058 (Porcine); 484186 (Canine); 102145573 (Cynomolgus Monkey)

Gene Symbol

CD274

UniProt

XP_005581836

Additional PD-L1/B7-H1 Products

Product Documents for Recombinant Cynomolgus Monkey PD-L1/B7-H1 Fc Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Cynomolgus Monkey PD-L1/B7-H1 Fc Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.